Comparison of Two Detoxification Protocols for Treatment of Medication-overuse Headache
NCT02903329 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2018-07-24
Summary
Medication-overuse headache (MOH) is a common, costly and disabling disorder affecting approximately 63 million people worldwide. MOH is a potentially treatable condition, and there are different opinions among headache specialists concerning the correct treatment strategy.
The study is a prospective longitudinal open-label randomized controlled study comparing two detoxification programs conducted in a tertiary headache care center. Patients with MOH are either randomized to treatment in program A or program B. In program A, patients undergo detoxification without any acute medication during a two months period (complete stop of acute medication intake). In program B, patients was allowed to take up to 2 days a week with analgesics or migraine medication during the two months detoxification period (restricted acute medication intake). Both A and B are out-patient programs, and patients in both groups receive patient education, consisting of six lessons, managed by specialized headache nurses in collaboration with specialized psychologists and physiotherapists (Figure 1). All patients are also offered rescue medication (levomepromazine or promethazine) and antiemetics, if necessary.
The need for prophylactic treatment is evaluated individually after 2-month detoxification. Patients are followed-up at 2, 6 and 12 months after detoxification. All patients are asked to continuously register headache calendar and to fulfill questionnaires at all the follow-up visits. In addition they are asked to fill out questionnaires (Headache Under-Response to Treatment (HURT), Hospital Anxiety and Depression Score (HADS), Severity of Dependence Score (SDS), World Health Organization Quality of Life Score(WHO QoL) and Dolo-score) at baseline, 2, 6 and 12 months
Conditions
- Medication-overuse Headache
Interventions
- OTHER
-
Detoxification
Two ways of composing the detoxification protocol
Sponsors & Collaborators
-
Danish Headache Center
lead OTHER
Principal Investigators
-
Louise Ninett Carlsen, MD · Danich Headache Center, Neurological department, Rigshospitalet-Glostrup
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2017-06-30
- Completion
- 2017-06-30
Countries
- Denmark
Study Locations
More Related Trials
-
Endocrinological Profile in Patients With Medication-overuse Headache Before and After Withdrawal Therapy
NCT04090333 ·Status: COMPLETED
-
Short Intervention for Medication Overuse Headache (MOH) - Pilot
NCT01078012 ·Status: COMPLETED ·Phase: NA
-
Brief Intervention for Medication Overuse Headache
NCT01314768 ·Status: COMPLETED ·Phase: NA
-
Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache
NCT00135122 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
NCT05452239 ·Status: COMPLETED ·Phase: PHASE4
-
China HeadAche DIsorders RegiStry
NCT05334927 ·Status: RECRUITING
-
Behavior Therapy vs Education for Persistent Headache After Mild TBI
NCT07229391 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The MOTS (Medication Overuse Treatment Strategy) Trial
NCT02764320 ·Status: COMPLETED ·Phase: NA
-
Medication Overuse Headache (MOH) and an Innovative Approach
NCT02435056 ·Status: COMPLETED ·Phase: NA
-
The Effects of Caffeine Withdrawal on Migraine
NCT03022838 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Medicine Abuse Headache
NCT01170793 ·Status: COMPLETED ·Phase: NA
-
Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches
NCT01406860 ·Status: TERMINATED ·Phase: NA
-
Intravenous Treatments Used in Medication Overuse Headache Bridge Treatment
NCT05608642 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Sumatriptan and Placebo on CGRP Induced Headache
NCT03542357 ·Status: COMPLETED ·Phase: NA
-
Hypersensitivity to Adrenomedullin in Post-Traumatic Headache
NCT07059546 ·Status: RECRUITING ·Phase: NA
-
Long-term Prognosis of Cluster Headache: a Retrospective Cohort Study
NCT02895256 ·Status: UNKNOWN
-
Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura.
NCT03075020 ·Status: COMPLETED ·Phase: NA
-
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
NCT00109083 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography
NCT02309606 ·Status: COMPLETED
-
Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache
NCT00274170 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Metoclopramide for Post Traumatic Headache
NCT03220958 ·Status: COMPLETED ·Phase: PHASE3
-
The Prolonged Use of Topiramate for Preventing Migraine Headaches
NCT00216619 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Medications for the Management of Acute Migraine Headache in the Emergency Department
NCT05983354 ·Status: UNKNOWN ·Phase: NA
-
Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
NCT00358839 ·Status: COMPLETED ·Phase: NA
-
CBT in Patients With Medication Overuse Headache
NCT01754571 ·Status: UNKNOWN ·Phase: EARLY_PHASE1